HIV-associated lipodystrophy commonly presents with fat loss in face, buttocks, arms and legs.

The exact mechanism of HIV-associated lipodystrophy is not fully elucidated.

Lipoatrophy occurs in HIV-associated lipodystrophy, one cause of which is an adverse drug reaction that is associated with some antiretroviral drugs.

HIV-associated lipodystrophy is a condition characterized by loss of subcutaneous fat associated with infection with HIV.

Tesamorelin (also known as Egrifta) is a synthetic form of growth-hormone-releasing hormone which is used in the treatment of HIV-associated lipodystrophy.

ARAA conducts clinical trials aimed at treating the medical disorders that accompany HIV, including HIV-associated lipodystrophy, diarrhea and neuropathy.

Both genetic (e.g., Berardinelli-Seip congenital lipodystrophy, Dunnigan familial partial lipodystrophy) and acquired (e.g., HIV-related lipodystrophy in patients treated with highly active antiretroviral therapy) forms of lipodystrophy may give rise to severe insulin resistance and many of metabolic syndrome's components.